NASDAQ:KITE - Kite Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$179.79 0.00 (0.00 %)
(As of 07/20/2018 06:54 AM ET)
Previous Close$179.79
Today's Range$179.79 - $179.79
52-Week Range$39.82 - $179.99
VolumeN/A
Average Volume1.65 million shs
Market Capitalization$10.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:KITE
CUSIPN/A
Phone+1-310-8249999

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01
Quick Ratio9.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,092.54%
Return on Equity-59.15%
Return on Assets-48.12%

Miscellaneous

Employees447
Outstanding Shares57,370,000
Market Cap$10,280.00

Kite Pharma (NASDAQ:KITE) Frequently Asked Questions

What is Kite Pharma's stock symbol?

Kite Pharma trades on the NASDAQ under the ticker symbol "KITE."

How were Kite Pharma's earnings last quarter?

Kite Pharma Inc (NASDAQ:KITE) announced its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to the consensus estimate of $5.74 million. Kite Pharma had a negative return on equity of 59.15% and a negative net margin of 1,092.54%. The company's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.54) earnings per share. View Kite Pharma's Earnings History.

What price target have analysts set for KITE?

7 brokers have issued 12-month price objectives for Kite Pharma's shares. Their forecasts range from $74.00 to $135.00. On average, they expect Kite Pharma's share price to reach $114.25 in the next twelve months. This suggests that the stock has a possible downside of 36.5%. View Analyst Ratings for Kite Pharma.

What is the consensus analysts' recommendation for Kite Pharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kite Pharma in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Who are Kite Pharma's key executives?

Kite Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

Has Kite Pharma been receiving favorable news coverage?

News headlines about KITE stock have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kite Pharma earned a coverage optimism score of 0.15 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Kite Pharma?

Shares of KITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kite Pharma's stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

How big of a company is Kite Pharma?

Kite Pharma has a market capitalization of $10.28 billion. Kite Pharma employs 447 workers across the globe.

How can I contact Kite Pharma?

Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  652 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  963
MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.